Exploration of Targeted Anti-tumor Therapy

Table 2

Comparison of clinico-pathological features between patients with good and poor SMD at baseline

Parameter		Total	Pre-chemotherapy SMD		Total	Post-chemotherapy SMD		P-value (sex)
Parameter		Total	Good (> 36.62)	Poor (≤ 36.62)	Total	Good (> 36.62)	Poor (≤ 36.62)	Baseline	Post-chemotherapy
BMI	< 18.5%	285	14	42	-	-	-	0.317	-
	18.5–24.99%		62	99
	25.0–29.99%		21	40
	≥ 30%		3	4
Smoker	Yes	285	18	41	274	18	35	0.408	-
Smoker	No	285	82	144	274	80	142	0.408	-
Age	≤ 65 Years	285	90	162	274	88	159	0.540	0.297
Age	> 65 Years	285	10	23	274	7	20	0.540	0.297
mALI	Good (> 55.33)	285	47	65	274	63	84	0.05	0.03
mALI	Poor (≤ 55.33)	285	53	120	274	38	89	0.05	0.03
Gender	Male	285	60	99	274	58	101	0.293	0.680
Gender	Female	285	40	86	274	43	83	0.293	0.680
ALI	Good (> 28.02)	285	42	66	-	-	-	0.294	-
ALI	Poor (≤ 28.02)	285	58	119	-	-	-	0.294	-
Sarcopenia	Yes	285	34	128	274	42	130	0	0
Sarcopenia	No	285	66	57	274	59	43	0	0
NLR	Good (≤ 3)	285	41	69	274	57	94	0.54	0.74
NLR	Poor (> 3)	285	59	116	274	44	79	0.54	0.74
Chemotherapy regimen received	Geftinib	285	50	93	-	-	-	0.96	-
Chemotherapy regimen received	Pemetrexed plus platins	285	50	92	-	-	-	0.96	-
Grades of drug toxicity	High grade	273	62	108	-	-	-	0.80	-
Grades of drug toxicity	Low grade	273	36	67	-	-	-	0.80	-
Performance status	0–1	285	98	170	-	-	-	0.07	-
Performance status	≥ 2	285	2	15	-	-	-	0.07	-
Progression	Yes	285	84	126	-	-	-	0.68	-
Progression	No	285	28	47	-	-	-	0.68	-
Final status	Alive	285	37	30	-	-	-	0	-
Final status	Dead	285	63	155	--	-	-	-	-

-: not applicable. Bold values indicate significant P-values